89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status
89bio 的肝病候選藥物 Pegozafermin 獲得 EMA 優先藥物地位
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊